Judge Du opened the can of worms knowing infringement was the primary indication the generics would be used for. Would be understandable if Amarin had ten or twenty years of protection to justly profit from its primary use that look so many years and millions in research to achieve.
Appeal courts got really lazy in reviews or refusal to review Amarin's arguments. GSK needed a trial not a review to get a common sense ruling that ruled in their favor.
Market Data 
Markets 
AI
